Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals is registering for resale up to 2,846,100,000 ordinary shares, represented by 24,861 American Depositary Shares (ADSs), held by existing shareholders. Separately, the company has begun a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including ADSs or pre-funded warrants plus two Series L warrants. Unit pricing is $3.28 per ADS unit and $3.2799 per pre-funded unit, with Series L warrants exercisable at $3.28 for five years and pre-funded warrants at $0.0001 per ADS. Net proceeds from this primary offering are expected to be about $8.75 million, intended for development programs, working capital and general corporate purposes. As of September 30, 2025, the company reported £2.79 million in cash and cash equivalents and later settled a previously disclosed advisor fee dispute via a payment. Assuming the offering closes and no warrants are exercised, 83,878,708,922 ordinary shares will be outstanding.
Biodexa Pharmaceuticals PLC has launched a best efforts public offering of 157,000 ADS Units and 2,891,781 Pre-Funded Units, each unit combining one ADS or pre-funded warrant with two Series L warrants. The company expects net proceeds of about $8.75 million, to be used to fund development programs, working capital and other general corporate purposes, with closing anticipated on or about December 19, 2025.
The Pre-Funded Warrants are exercisable at $0.0001 per ADS, while the Series L and related placement agent warrants are exercisable at $3.28 per ADS and expire five years after issuance, subject to 4.99% or 9.99% beneficial ownership limits. As of September 30, 2025, the company reported unaudited cash and cash equivalents of £2.79 million, and after the offering closes, it expects to have 83,878,708,922 ordinary shares outstanding assuming no warrant exercises.
Biodexa Pharmaceuticals PLC is registering up to 5,923,377,900,000 Ordinary Shares in the form of American Depositary Shares to support a best-efforts public offering of up to 3,536,345 Units or Pre-Funded Units. Each Unit includes one Depositary Share (representing 100,000 Ordinary Shares) and one Series L warrant with an initial exercise price set at 225% of the Unit price, plus complex reset and "zero cash exercise price" features that can sharply increase shares issued without bringing in additional cash.
The company estimates net proceeds of about $15.5 million if all Units are sold, to fund its drug development programs, working capital and general corporate purposes. As of December 1, 2025, it had 68,178,708,922 Ordinary Shares outstanding, and if all Ordinary Shares offered were issued they would equal roughly 98.9% of that total, meaning very high potential dilution. Biodexa is a clinical-stage biotech focused on eRapa for familial adenomatous polyposis and non‑muscle invasive bladder cancer, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers, with eRapa already in a Phase 3 FAP trial and supported by a $3.0 million CPRIT grant and FDA fast track status. Cash and cash equivalents were £2.79 million as of September 30, 2025, based on unaudited figures.
Biodexa Pharmaceuticals PLC is registering 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares for resale by holders of Series D warrants issued in a June 2023 private placement. The company is not selling any Depositary Shares in this offering and will not receive proceeds from shareholder resales, although it could receive up to $4.4 million if all Series D Warrants are exercised for cash.
Ordinary Shares outstanding were 61,952,308,922 as of November 1, 2025. Biodexa is a clinical-stage biopharmaceutical company focused on eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, and tolimidone for type 1 diabetes, while MTX110 for rare brain cancers has been de-prioritized. eRapa has FDA fast track designation and European orphan drug designation, with an ongoing Phase 3 FAP trial and Phase 2 NMIBC study.
As of September 30, 2025, Biodexa reported unaudited cash and cash equivalents of £2.79 million. The prospectus highlights that large-scale resale of shares could pressure the market price and that future issuances may dilute existing holders.
Biodexa Pharmaceuticals (BDRX) has filed a resale registration covering 171,700,000 Ordinary Shares represented by 1,717 American Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement. All sale proceeds for these shares will go to the selling shareholders; Biodexa would receive only any cash exercise proceeds at an exercise price of $0.025 per share.
Ordinary Shares outstanding were 61,952,308,922 as of November 1, 2025. Biodexa is a clinical-stage biopharmaceutical company focused on eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, and tolimidone for type 1 diabetes, with MTX110 for rare brain cancers de-prioritized due to resource constraints.
eRapa has fast track designation from the U.S. FDA and orphan drug designation in Europe for FAP, with a Phase 3 study underway and supported by a $3.0 million CPRIT grant. As of September 30, 2025, cash and cash equivalents were £2.79 million, highlighting the importance of external funding sources for ongoing development. The company does not expect to pay dividends in the foreseeable future.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to its Form F‑1 to update a resale registration for 171,700,000 Ordinary Shares represented by 1,717 American Depositary Shares issuable on exercise of December 2023 pre-funded warrants. All sale proceeds from these shares go to the selling shareholders, though the company may receive cash if the warrants are exercised at an exercise price of $0.025 per share.
The amendment refreshes disclosure with the latest business and financial information, including progress on eRapa, which has FDA fast track designation for non‑muscle invasive bladder cancer and European orphan drug designation for familial adenomatous polyposis, and a CPRIT grant of $3.0 million to support a Phase 3 FAP program. Biodexa is also running a Phase 2a study of tolimidone in type 1 diabetes and has de‑prioritized MTX110 due to resource constraints. As of September 30, 2025, cash and cash equivalents were £2.79 million, and as of November 1, 2025, there were 61,952,308,922 Ordinary Shares outstanding.
Biodexa Pharmaceuticals plc is conducting a best efforts primary offering of up to 3,377,110 Units or Pre-Funded Units and related warrants, registering up to 5,724,837,950,000 Ordinary Shares in the form of American Depositary Shares. As of June 30, 2025, 61,952,308,922 Ordinary Shares were outstanding, so the registered shares would represent about 98.9% of the then outstanding total if all were issued.
Each Unit includes one Depositary Share and one Series L Warrant with anti-dilution, reset and zero cash exercise price features that can sharply increase the number of shares issued while providing little or no additional cash to the company. Assuming all Units are sold at an assumed $5.33 per Unit, net proceeds are estimated at about $15.5 million, to be used mainly to fund development of eRapa and tolimidone, and for working capital and general corporate purposes.
The company highlights significant potential dilution, the risk that the warrant structure and large share registration could pressure its NASDAQ listing, and notes that it does not expect to pay dividends, so returns would depend on share price performance.